Polypeptides and methods for the specific detection of antibodies in patients with a borrelia infection

ABSTRACT

The present disclosure relates to proteins derived from OspC from bacteria of the genus  Borrelia , in particular a protein which comprises a first OspC polypeptide, wherein the first OspC polypeptide is linked to a second OspC polypeptide via a disulphide bridge. The disclosure also relates to a method for the detection of antibodies against OspC and a method for the detection of a  Borrelia  infection, wherein a protein according to the disclosure is employed, and also to a diagnostic kit and a vaccine against  Borrelia.

CROSS-REFERENCES TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 12/636,530, filed Dec. 11, 2009, now issued as U.S. Pat. No. 8,163,500 which application claims the benefit under 35 U.S.C. §119 of European Patent Application No. 08021660.9, filed Dec. 12, 2008, where these applications are incorporated herein by reference in their entireties.

STATEMENT REGARDING SEQUENCE LISTING

The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is 310159_(—)404D1 SEQUENCE_LISTING_.txt. The text file is 29 KB, was created on Mar. 19, 2012, and is being submitted electronically via EFS-Web.

BACKGROUND

1. Technical Field

The present disclosure relates to polypeptides derived from OspC (“outer surface protein C”) from bacteria of the genus Borrelia, in particular a protein which comprises a first OspC polypeptide, wherein the first OspC polypeptide is linked to a second OspC polypeptide via a disulphide bridge. The disclosure also relates to a method for the detection of antibodies against OspC and a method for the detection of a Borrelia infection, wherein a protein according to the disclosure is employed, and also to a diagnostic kit and a vaccine against Borrelia.

2. Description of the Related Art

Bacteria of the genus Borrelia are described as pathogens of several human diseases, in particular as pathogens of Lyme borreliosis and of relapsing fever. An infection nowadays is usually detected via determination of specific antibodies against the bacteria in human or animal body fluids. In this context, the presence of specific antibodies against antigens which occur only in Borrelia indicates an infection with Borrelia. Early phases of infection, in particular fresh infections up to four weeks after initial contact, are characterized by the presence of antibodies of the IgM class, in particular against the antigens OspC, p41 (flagellin) and P39 (BmpA), while late phases, in particular infections which have run their course, have been cured or are chronically manifest, are accompanied by the presence of antibodies of the IgG class, in particular against the antigens VIsE, p83/P100, p58, OspA, p41 (flagellin), P39, P18 and others (Wilske and Fingerle, 2005).

An early diagnosis of the disease is particularly important because therapy with antibiotics is more successful and easier in the early stages than in late stages, thus, e.g. in the early phase, an oral therapy with antibiotics is still possible.

Antibodies against OspC of the IgM class are generally the most important marker for an early phase of the disease. Native OspC is a membrane protein of the lipoprotein family 6 acylated with a fatty acid, which is anchored in the outer cell membrane (Norris et al., 1992; Hagman et al., 1998). During expression, in parallel with the cleavage of the signal sequence by signal peptidase II, the acyl residue is attached to the only conserved cysteine occurring in the OspC amino acid sequence (Wu and Tokunaga, 1986). It serves for anchoring in the lipid-containing cell membrane.

A conserved C-terminal peptide of ten amino acid residues, the terminal carboxyl group of which must be freely accessible, is generally regarded as the most important epitope within OspC for reactions with human antibodies of the IgM class (Mathiesen et al., 1998a; Mathiesen et al., 1998b), as is also described in the PCT patent specification WO 9742221. Epitopes in the poorly conserved central region of OspC are also described (Earnhart et al., 2005).

For detection of the antibodies, antigens purified from Borrelia are regularly used in immunobiochemical tests, such as ELISA, line blot or western blot. In the methods, individual or several antigens are conventionally bound to a solid phase and brought into contact with the body fluid to be analysed, and the bound antibodies are detected by a reporter molecule. Such kits are marketed e.g. by EUROIMMUN AG as EUROLINE-WB and Anti-Borrelia-plus-VIsE-ELISA. Similar methods are described in the literature (Hansen et al., 1988; Cutler and Wright, 1989; Fister et al., 1989).

Methods which are based on non-recombinant preparations can be reproduced only with a high outlay and are therefore cost-intensive, because essentially complex culture media which contain natural constituents which are not chemically defined, such as protein-containing serum fractions from Mammalia and complex protein mixture, e.g. proteolytically treated muscle extracts, yeast extracts or gelatine, are used for in vitro culturing of Borrelia. A commercial kit on this basis is obtainable e.g. from Sigma Aldrich (Complete BSK-H). Similar compositions are described in the literature with the designations MKP and BSK II (Ruzic-Sabljic and Strle, 2004).

Unfortunately, the constituents of these media which are not chemically defined are subject to marked variations in their compositions from batch to batch, are at risk of contamination with viruses or Mycoplasma and are cost-intensive to produce. Accordingly, Borrelia cultured in vitro conventionally show marked variations in their growth rates and their gene expression patterns, depending on the particular culture media used or depending on individual components of the particular culture media used. Genes which are expressed in vivo, depending on the particular host organism, are particularly affected by this (Pollack et al., 1993; Yang et al., 2001). This applies in particular to OspC. The culturing temperature and the oxygen and carbon dioxide concentration furthermore also have a decisive influence on the nature and amount of the proteins expressed (Seshu et al., 2004; Hyde et al., 2007). As a result, in particular the results from different laboratories which culture Borrelia can be poorly compared with one another.

Methods which are based on individual antigens purified from Borrelia cultured in vitro are furthermore susceptible to non-specific reactions caused by the presence of further impurities which have not been adequately depleted. In particular, in methods which only generate one signal, such as, for example, ELISA or line blot, falsely positive results are thus regularly obtained. In contrast, western blots, which bypass this problem by local resolution of the signals, have the disadvantage that they generate a considerable additional effort due to the required electrophoresis and the transfer to a membrane.

In further methods, antigens are used which are prepared by recombinant techniques, e.g. by heterologous expression of antigens or antigen fragments in E. coli, as described e.g. in the European patent specification EP 0506868. Commercially obtainable variants are e.g. EUROLINE-WB and Anti-Borrelia-plus-VIsE-ELISA (IgG) and the recomline Borrelia IgM (Mikrogen). Similar methods are described in the literature (Hauser et al., 1998; Lawrenz et al., 1999; Wilske and Fingerle, 2005). In general, recombinant antigens have the advantage that they can be purified in a more defined manner and with less effort than native antigens, e.g. by fusion with purification polypeptides, e.g. the polyhistidine-tag (=His-tag).

Heterologous expression of OspC including its intrinsic signal sequence in E. coli and subsequent acylation is possible, but leads to a low expression efficiency (Fuchs et al., 1992). For this reason, in general deletion constructs of OspC with increased expression efficiency in which at least the signal sequence is missing are employed. In this context, in the prior art, at least the first 19 amino acids of OspC, including the cysteine which occurs in the OspC amino acid sequence, are deleted (Fuchs et al., 1992; Wilske et al., 1993; Wilske et al., 1995; Eicken et al., 2001; Kumaran et al., 2001), and this is in some cases supplemented by N-terminal fusion with heterologous polypeptides, e.g. the His-tag.

Such N-terminally shortened variants have also been used for clarification of the spatial structure of OspC (Kumaran et al., 2001; Eicken et al., 2001). For this, the first 31 (Eicken et al., 2001) or 37 (Kumaran et al., 2001) amino acid residues of OspC were deleted in the recombinant OspC variants in order to achieve in particular a suitable amount and purity of the OspC. The two exemplary spatial structures indicate that recombinant OspC tends to dimerize. This dimerization takes place on the basis of ionic interactions and hydrogen bridge bonds, but not by a covalent linking.

There are also attempts to prepare acylated variants of OspC recombinantly by upstream insertion of a heterologous signal sequence, as described e.g. in the European patent specification EP 1741718. By attaching the fatty acid, such OspC variants are intended to have a higher in vivo immunogenicity than the N-terminally deleted or modified OspC variants described until then.

The recombinant variants of OspC used hitherto for diagnostics in general have the disadvantage that they differ from the native OspC purified from Borrelia cultured in vitro, because they are not or are differently modified post-translationally, and the presence of conformational epitopes or the accessibility of epitopes in general is not comparable or not guaranteed. The manifestation of these disadvantages is the lower specific reactivity of recombinant OspC variants used to date compared with non-recombinant preparations, which is regularly described in the literature. It is reflected in high rates of false positive results in such diagnostic methods.

The development of recombinant OspC variants which, with an easier and more defined preparation compared with the native antigens, can be employed in diagnostic methods and at the same time do not lead to the disadvantages described for the recombinant OspC variants to date is therefore necessary in order to facilitate the preparation of such in vitro diagnostic agents or the implementation of such diagnostic methods and to standardize the results of different laboratories.

BRIEF SUMMARY

In one aspect, the present disclosure provides a protein that comprises a first OspC polypeptide and a second OspC polypeptide, wherein the first OspC polypeptide is linked to the second OspC polypeptide via a disulphide bridge.

In another aspect, the present disclosure provides a method for detecting antibodies in a biological sample against the above-described protein, comprising: contacting the biological sample with the protein, and detecting binding of antibodies to the protein.

In another aspect, the present disclosure provides a method for diagnosing a Borrelia infection, comprising contacting a biological sample of a patient with the above-described protein, and determining the presence or absence of binding of antibodies that may be in the sample to the protein, wherein the presence of the binding of antibodies to the protein indicates a Borrelia infection.

In another aspect, the present disclosure provides a kit for diagnosing a Borrelia infection, comprising the above-described protein.

In another aspect, the present disclosure provides a method for vaccinating against a Borrelia infection, comprising administering the above-described protein to a patient.

In another aspect, the present disclosure provides a vaccine against a Borrelia infection, comprising the above-described protein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows an alignment of mature OspC from B. afzelii VS461=OspC_(VS461) (SEQ ID NO:3), from B. garinii 20047=OspC₂₀₀₄₇ (SEQ ID NO:6) and from B. burgdorferi B31=OspC_(B31) (SEQ ID NO:9), determined with CLUSTAL 2.0.10 with standard settings. The table shows the degree of amino acid identity.

FIG. 2 shows by way of example a western blot with the non-reduced variants His-m-OspC_(VS461) and His-m-Cys-OspC_(VS461) after staining with Ponceau S (track 1-3) and after incubation with a serum of a patient with a borreliosis in the early stage (1:200 dilution) and detection of the bound IgM antibodies (track 4 & 5). Track 1: size marker Mark12 (Invitrogen), track 2 & 4: 15 μg of His-m-OspC_(VS461), track 3 & 5: 25 μg of His-m-Cys-OspC_(VS461).

DETAILED DESCRIPTION

It has now been found, surprisingly, that the problems described can be solved by the disclosure, in particular the subject matter of the claims.

The disclosure provides a protein comprising a first OspC polypeptide, wherein the first OspC polypeptide is covalently linked to a second OspC polypeptide. It has proved advantageous in the context of the disclosure if the first OspC polypeptide is linked to a second OspC polypeptide via a disulphide bridge.

An OspC polypeptide in the context of the disclosure, in particular the first and/or second OspC polypeptide, can have an amino acid identity of at least 70% with SEQ ID NO:3, SEQ ID NO:6 or SEQ ID NO:9 and is recognized (in this homologous region) specifically by antibodies against OspC from Borrelia. Preferably, the amino acid identity is at least 80%, at least 90%, at least 95% or at least 99% to one or more of the sequences according to SEQ ID NO:3, SEQ ID NO:6 or SEQ ID NO:9. These sequences correspond to the native OspC sequences from the three type strains of the Borrelia genospecies Borrelia afzelii (VS461), Borrelia garinii (20047) and Borrelia burgdorferi (B31). The amino acid identity between these strains is 70% and 76% (see FIG. 1). The amino acid identity is preferably determined with the program CLUSTAL 2.0.10 with standard settings. In the context of the disclosure, in particular, an OspC sequence from another Borrelia strain, e.g. PKo, or a variant thereof can be employed, the specific binding by antibodies against OspC from Borrelia being decisive.

In the context of the disclosure, a specific recognition by antibodies against OspC from Borrelia means that under conditions suitable for this, which are known to the person skilled in the art and described, for example, in the examples, antibodies against OspC from Borrelia bind to the polypeptide or protein, but not to another unrelated protein. Serum from patients with a confirmed early phase of a Borrelia infection can be employed, for example, as antibodies against OspC from Borrelia, as can antibodies which have been produced e.g. by immunization of mice or rabbits with native purified OspC (e.g. EUROIMMUN), in particular polyclonal antibodies.

Borrelia includes all bacteria of the genus Borrelia, and B. burgdorferi, B. garinii and B. afzelii are mentioned by way of example.

An OspC polypeptide in the context of the disclosure, in particular the first and/or second OspC polypeptide, may comprise at least one epitope which is specifically recognized by antibodies against OspC from Borrelia, the epitope comprising at least a partial sequence of 10 contiguous amino acids from SEQ ID NO:3, SEQ ID NO:6 or SEQ ID NO:9, in particular the 10 C-terminal amino acids of these sequences. Preferably, the partial sequence comprises the epitope described as immunodominant in Mathiesen et al., 1998a; Mathiesen et al., 1998b. In particular, the OspC polypeptide(s) comprise(s) one of the amino acid sequences according to SEQ ID NO:2, SEQ ID NO:5 or SEQ ID NO:8 in the C-terminal location. It is preferable for the OspC polypeptide(s) to end at the C-terminus with the sequence of the native OspC, that is to say no further amino acids which could impede the recognition of the C-terminal epitope are contained here.

Alternatively or in addition, one or more further epitopes, e.g. as described by Earnhart et al., 2005, can be present in the OspC polypeptide.

Preferably, the epitope is or the epitopes are embedded in further sequences from OspC corresponding to a wild type sequence from OspC from Borrelia. Preferably, the partial sequence of contiguous amino acids from SEQ ID NO:3, SEQ ID NO:6 or SEQ ID NO:9 has a length of at least 15, at least 20, at least 25, at least 30, at least 50, at least 100, at least 150 or at least 190 amino acids. Preferably, these are the C-terminal amino acids from SEQ ID NO:3, SEQ ID NO:6 or SEQ ID NO:9, from homologues from other Borrelia strains or homologues with a sequence identity of at least 70%, at least 80%, at least 90%, at least 95% or at least 99% with SEQ ID NO:3, SEQ ID NO:6 or SEQ ID NO:9.

The OspC polypeptides according to the disclosure contain no signal sequences for an acylation. Polypeptides expressed in the prior art (EP 1741718) which, like the wild type polypeptide, were to be acylated on the furthest N-terminally located cysteine, were expressed with a heterologous signal sequence. In contrast, the polypeptide according to the disclosure contains neither a homologous signal sequence nor a heterologous signal sequence. Signal sequences which lead to an acylation conventionally comprise a Braun's signal sequence which is recognized by signal peptidase II. Such signal sequences can comprise e.g. the sequence L-I-A-C (as OspA or OspB) or L-X-Y-C (wherein X and Y are small neutral amino acids) (Fuchs et al., 1992). Preferably, the polypeptide according to the disclosure also was not expressed with an acylation sequence, this then being split off. The OspC polypeptide according to the disclosure is therefore also not acylated. In one embodiment of the disclosure, the cysteine on which the acylation would take place in the wild type OspC is the cysteine on which the disulphide bridge to a further OspC polypeptide is formed.

Alternatively or in addition, a disulphide bridge can also be formed on another cysteine. Preferably, the disulphide bridge is formed by bonding of a cysteine which is not more than about 100, preferably not more than about 50 or not more than about 30 amino acid positions from the N-terminus of the OspC polypeptide. In particular, the disulphide bridge can be formed on a cysteine which forms the N-terminus of the polypeptide or is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acids away from the N-terminus.

In order to facilitate the purification of the protein according to the disclosure, in one embodiment, on the N-terminus, in particular N-terminally from the cysteine on which the disulphide bridge is formed, the OspC polypeptide/the OspC polypeptides contain/contains a His-tag, which can have e.g. the sequence corresponding to the first 12 amino acids of SEQ ID NO:1. Instead of 8, e.g., 6 or 10 histidines can also be employed. Other amino acid sequences known in the prior art which facilitate purification or detection of the protein, e.g. a Flag-tag, can also be incorporated here. Such sequences should not impede the recognition by antibodies against OspC from Borrelia. Under this prerequisite, bonding or incorporation of a reporter molecule is also possible at another location in the molecule. The reporter molecule can be chosen, e.g., from a group comprising His-tag, Flag-tag, a fluorescence label, biotin and streptavidin.

In one embodiment, the first OspC polypeptide N-terminally comprises a His-tag, which is adjacent to a cysteine which is bonded to the second OspC polypeptide in the protein according to the disclosure via a disulphide bridge, and following this in the polypeptide chain of the first OspC polypeptide, the further sequence of an OspC polypeptide from a Borrelia strain, e.g. B. burgdorferi, B. afzelii or B. garinii, this sequence forming the C-terminus of the polypeptide. In particular, the OspC polypeptide can consist of these sequences. The second (and optionally further) OspC polypeptide preferably comprises the same sequence constituents (His-tag-Cys-OspC sequence) or consists of these.

In a preferred embodiment, the first and/or the second OspC polypeptide contains a sequence according to SEQ ID NO:2, SEQ ID NO:5 or SEQ ID NO:8.

In the context of the present disclosure, “a” in general is not used as a numerical word, but an indeterminate number can be described by this. Unless described otherwise, it can thus also represent two or more. In particular, in the context of the disclosure an OspC polypeptide is understood as meaning the first and/or the second OspC polypeptide of a protein according to the disclosure. This does not exclude the presence of further OspC polypeptides, which preferably have the same structure as the first OspC polypeptides.

Preferably, the proteins according to the disclosure are dimers of two OspC polypeptides. Multimerization with further OspC polypeptides or other molecules (e.g. via additional disulphide bridges) is also in principle possible, as long as this does not impede or restrict the recognition by antibodies against OspC from Borrelia. It has been demonstrated in the context of the disclosure that by means of the disulphide bridge, a homodimer of two identical OspC polypeptides or a heterodimer of different OspC polypeptides can be formed. With a protein according to the disclosure, it is therefore possible e.g. to conduct the detection of antibodies against several Borrelia strains, or to prepare a vaccine against several Borrelia strains.

With respect to the present disclosure, protein is in general used for multimers of OspC polypeptides and polypeptide for individual OspC polypeptide chains, but both terms, as can be seen by the person skilled in the art from the context in each case, can also relate to proteins, polypeptides or peptides according to general scientific usage, no differentiation being made between different sizes.

In the context of the disclosure, it has been demonstrated that the disulphide bridge bond directly between the OspC polypeptides significantly improves the recognition by antibodies against OspC from Borrelia. Associated with this, the recognition of the protein by antibodies against OspC from Borrelia is reduced by bringing it into contact with at least one reagent which destroys the disulphide bridge. In particular, such a reagent is chosen from a group comprising thiol-containing reagents or a combination of a thiol-containing reagent and an alkyl halide. Such reagents include e.g. reducing agents, such as dithiothreitol or mercaptoethanol, optionally in combination with an alkylating agent, such as iodoacetamide. In particular, a reducing agent can first be employed, and then an alkyl halide.

A protein according to the disclosure can be produced e.g. in bacterial cells (e.g. E. coli, e.g. E. coli RosettaBlue(DE3)pLacl (Stratagene)), insect cells (e.g. SF6 cells), yeast cells (e.g. S. cerevisiae) or cells of vertebrates (e.g. CHO cells). The disclosure includes a method for the production of the protein according to the disclosure wherein this is recombinantly expressed and purified. Purification is possible e.g. via affinity chromatography, it being possible to use, for example, antibodies against OspC from Borrelia or—if e.g. a His-tag is used—a nickel affinity chromatography. Preferably, non-reducing conditions are used for the expression and/or purification. Preferably, a pH of 7-9, a pH of 7.5-8.5, in particular pH 8 is used during the purification. In an affinity chromatography e.g. the mixture to be purified can be applied and washed with TNI10 buffer, and the protein can be eluted with TNI150 buffer. Other production and purification methods which do not impede the formation of the disulphide bridge are known in the prior art.

In one aspect, the present disclosure relates to a method for the detection of antibodies against a protein according to the disclosure, in which a biological sample is brought into contact with the protein according to the disclosure, and binding of antibodies, which may possibly be present in the sample, to the protein is detected.

In particular, a method for the diagnosis of a Borrelia infection is disclosed, in which a biological sample from a patient is brought into contact with a protein according to the disclosure, and binding of antibodies which may possibly be present in the sample to the protein is detected, wherein detection of the binding of antibodies indicates a Borrelia infection.

The disclosure also provides the use of a protein according to the disclosure for the detection of antibodies against OspC of Borrelia and for the diagnosis of a Borrelia infection. The antibodies detected are preferably antibodies of the IgM type, by which means a Borrelia infection in an early phase is detected.

The binding of the antibodies can be detected e.g. with an immunofluorescence test, ELISA, luminescence test, western blot, line blot or dot blot. The biological sample employed can be e.g. a body fluid of a patient, in particular blood, serum, plasma, saliva, urine or cerebrospinal fluid. Preferably, the patient is a human or animal patient who is to be tested, for example, for an infection with Borrelia.

The disclosure also provides a kit for the diagnosis of Borrelia infections comprising a protein according to the disclosure. Such a kit can furthermore comprise antibodies against OspC from Borrelia and/or buffers and/or reagents suitable for the detection, such as e.g. an antibody which recognizes human IgM, optionally marked with a reagent suitable for the detection (e.g. a fluorescent dye, such as FITC or PE, an enzyme, such as alkaline phosphatase or horseradish peroxidase, or biotin). It can be e.g. a kit for an immunofluorescence test, ELISA, luminescence test, western blot, line blot or dot blot.

The disclosure also provides the use of a protein according to the disclosure for the preparation of a vaccine against a Borrelia infection, and a vaccine against a Borrelia infection comprising a protein according to the disclosure. Such a vaccine may comprise suitable auxiliary substances, buffers and/or adjuvants. It can be a combination vaccine which, for example, can be directed against two, three or more Borrelia strains. This can be achieved by the use of heteromeric OspC proteins, but also e.g. by mixing various homodimers. Such a vaccine can be formulated e.g. for subcutaneous, intramuscular, intravenous or oral administration. Multiple administration, e.g. twice, three times or four times (for example on day 1, 14, 28, 42), may be appropriate in order to improve the formation of antibodies.

The present disclosure for the first time makes it possible to determine OspC-specific antibodies with the aid of recombinant OspC variants which give results which are diagnostically equivalent to the use of non-recombinant OspC variants. At the same time, the use of the novel recombinant OspC variants with disulphide bridges makes a considerable reduction in the effort for the production of the antigens possible, compared with the native OspC variants which were hitherto regarded as diagnostically the most competent.

It has been found that the OspC variants according to SEQ ID NO:1, SEQ ID NO:2 (derived from mature OspC according to SEQ ID NO:3 from B. afzelii VS461=OspC_(VS461), Genbank Accession No. D49379), SEQ ID NO:4, SEQ ID NO:5 (derived from OspC according to SEQ ID NO:6 from B. garinii 20047=OspC₂₀₀₄₇, Genbank Accession No. L42900), SEQ ID NO:7 and SEQ ID NO:8 (derived from OspC according to SEQ ID NO:9 from B. burgdorferi B31=OspC_(B31), Genbank Accession No. U01894) can be expressed in large amounts in E. coli and can be prepared with a high purity. No difference was found in this context in the effort for the genetic engineering work, expression rate, effort for the preparation or purity between the variants according to SEQ ID NO:1 and SEQ ID NO:2 (derived from OspC_(VS461)), SEQ ID NO:4 and SEQ ID NO:5 (derived from OspC₂₀₀₄₇) and SEQ ID NO:7 and SEQ ID NO:8 (derived from OspC_(B31)), which in each case differ by only one cysteine.

It has moreover been demonstrated by way of example that the diagnostic accuracy of a method for the determination of antibodies of the IgM class using the variant according to SEQ ID NO:2 derived from OspC_(VS461) surprisingly is equivalent to an established method using non-recombinant OspC of the strain VS461. It has furthermore been demonstrated that the diagnostic accuracy of these two methods is greater than in methods which use the variant according to SEQ ID NO:1 derived from OspC_(VS461) or recombinant OspC variants deleted in accordance with the scientific literature.

It has furthermore been demonstrated by way of example that the variant according to SEQ ID NO:2 derived from OspC_(VS461) is present in a form dimerized via a disulphide bridge after biochemical purification, and that it surprisingly has a higher specific reactivity than its monomer, its monomer acetylated on the cysteine and the analogous monomer according to SEQ ID NO:1.

It has furthermore been demonstrated by way of example that by mixing the variants according to SEQ ID NO:2 (derived from OspC_(VS461) and SEQ ID NO:5 (derived from OspC₂₀₀₄₇), followed by reduction thereof and subsequent oxidation, heterodimers with disulphide bridges can be prepared, the usability of which is in principle equivalent to the homodimers with disulphide bridges, but which have the advantage of being able to detect several different species-specific antibodies, i.e. antibodies directed exclusively against OspC from B. afzelii strains or exclusively against OspC from B. garinii strains. Means and methods for separating heterodimers from homodimers, e.g. by isoelectric focussing, are accessible to the person skilled in the art. Such a separation is however not necessary, since mixtures of homodimers and heterodimers can also be used.

It has furthermore been demonstrated by way of example that mice surprisingly have a higher titre of antibodies against Borrelia after immunization with the OspC variant according to SEQ ID NO:2 (derived from OspC_(VS461)) dimerized via disulphide bridges than after immunization with the same amount of the monomeric OspC variant according to SEQ ID NO:1. A higher effectiveness of vaccines based on the polypeptides according to the disclosure can be concluded from this. The results can be applied to the other variants, to other animals and to humans.

The following examples present the subject matter of the disclosure by way of example, but are not intended to limit the disclosure. Modifications are obvious to the person skilled in the art. All the publications cited are included explicitly by the reference.

EXAMPLES Example 1 Cloning of Vectors for Expression of OspC in E. coli

OspC is coded on plasmid B in Borrelia (nomenclature on the basis of the complete B. burgdorferi genome, reading frame BB_B19). Total DNA from B. afzelii strain VS461, B. garinii strain 20047 and B. burgdorferi strain B31 is used as the template for PCR amplification of gene regions according to SEQ ID NOS:10 to 15 coding for six OspC variants. The primer combinations according to SEQ ID NO:16 and SEQ ID NO:17 (His-m-OspC_(VS461)), SEQ ID NO:18 and SEQ ID NO:17 (His-Cys-m-OspC_(VS461)), SEQ ID NO:19 and SEQ ID NO:20 (His-m-OspC₂₀₀₄₇), SEQ ID NO:21 and SEQ ID NO:20 (His-Cys-m-OspC₂₀₀₄₇), SEQ ID NO:22 and SEQ ID NO:17 (His-m-OspC_(B31)) and SEQ ID NO:23 and SEQ ID NO:17 (His-Cys-m-OspC₃₁) are employed for amplification of the individual variants. By the PCR, the necessary restriction cleavage sites are integrated into the amplificates at the 5′ and 3′ end of the coding strand, respectively.

The PCR is carried out on a 50 μl scale using the “High Fidelity PCR Enzyme Mix” (Fermentas) according to the manufacturer's instructions. 30 reaction cycles composed of steps 1 to 3 are carried out:

Step 1 30 seconds 94° C. Step 2 45 seconds 56° C. Step 3 30 seconds 72° C.

The PCR fragments are then purified using the NucleoSpin® Extract II purification system (MACHEREY-NAGEL GmbH & Co. KG) in accordance with the manufacturer's instructions and taken up in each case in 50 μl of 5 mM Tris-HCl pH 8.5. The fragments are then cleaved at the ends by restriction endonucleases. The restriction endonucleases are obtained from Fermentas and employed in accordance with the manufacturer's instructions.

The amplificates are treated with restriction endonucleases as follows:

His-m-OspC_(VS461): Ncol and Xhol,

His-Cys-m-OspC_(VS461): Esp3I and Xhol,

His-m-OspC₂₀₀₄₇: Ncol and Xhol,

His-Cys-m-OspC₂₀₀₄₇: Esp3I and Xhol,

His-m-OspC_(B31): Ncol and Xhol,

His-Cys-m-OspC_(B31): Pagl and Xhol.

The PCR fragments are then purified using the NucleoSpin® Extract II purification system in accordance with the manufacturer's instructions and taken up in 50 μl of 5 mM Tris-HCl pH 8.5, respectively.

The enzymatically cleaved and purified PCR fragments are then integrated into Ncol/Xhol-cleaved plasmid according to SEQ ID NO:24 by ligation. The Rapid DNA Ligation Kit from Fermentas is employed for the ligation in accordance with the manufacturer's instructions. The ligation batch is transformed into E. coli RosettaBlue(DE3)pLacl (Stratagene).

Positive clones are selected on the basis of kanamycin/chloramphenicol [50/34 μg/ml] resistance. The plasmids contained in these clones are isolated from them and checked by restriction analysis and DNA sequencing. Correct plasmids are chosen for carrying out the expression, inoculated into 20 ml of LB medium containing antibiotics and incubated at 37° C. until an OD600 (d=1 cm) of 0.6 is reached. The protein expression is induced by addition of IPTG (final concentration: 1 mM) and incubation is then carried out for a further 3 hours at 37° C. After this time, the cells are sedimented by centrifugation at 2,200×g for 10 minutes, resuspended in 20 ml of PBS, centrifuged again and finally resuspended in 1 ml of PBS.

The cells are broken down by addition of one third volume of 4×NuPAGE-LDS sample buffer (Invitrogen), containing 141 mM Tris-HCl pH 8.5, 2%) (w/v) lithium dodecyl sulphate, 10% (w/v) glycerol, 0.51 mM EDTA, 0.22 mM SERVA Blue G250, followed by incubation for 10 minutes at 70° C. Chromosomal DNA is then fragmented by ultrasound treatment (Branson Sonifier, level 7, MicroTip).

After separation by SDS-PAGE, the cell lysate is transferred to a nitrocellulose membrane. Non-saturated positions of the membrane are then blocked by incubation with “universal buffer” (EUROIMMUN) with 3% (w/v) milk powder for 15 minutes. Incubation is then carried out for 1 hour with a monoclonal antibody from the mouse (Merck Biosciences GmbH) directed against the His-tag and diluted 1:2,000 in “universal buffer” with 3% (w/v) milk powder. Washing is then carried out with “universal buffer” three times for 5 minutes each time. In a second incubation step, the antibodies bound to the proteins in the positive case react with a conjugate solution which is diluted 1:2,000 in “universal buffer” and contains as the conjugate an anti-mouse IgG antibody labelled with alkaline phosphatase (Sigma). Washing is then carried out as after the anti-His-tag incubation. In a third incubation step, the bound antibodies are then detected with an NBT/BCIP “substrate solution” (4-nitroblue tetrazolium chloride/chlorobromoindolyl phosphate, EUROIMMUN).

Results:

In the western blot after reducing SDS-PAGE, the expression of the recombinant constructs can be detected by the presence of His-tag-reactive proteins, the sizes of which are in good agreement with the masses of 23-25 kDa predicted on the basis of the amino acid sequences. Cells which contain the unchanged plasmid vector contain no corresponding protein.

Example 2 Purification of Recombinant OspC Variants by Affinity Chromatography

The affinity column is a NiNTA spin column (Qiagen) handled in accordance with the manufacturer's recommendations.

The cells harvested according to Example 1 are centrifuged again as described, resuspended in 1 ml of “TNI10 buffer” (5 mM Tris-HCl pH 8.0; 300 mM NaCl; 10 mM imidazole) and broken down by three ultrasound treatments of one minute (Branson Sonifier, level 7, MicroTip). 0.5 ml of the supernatant is applied to a NiNTA spin column equilibrated with “TNI10 buffer”.

Non- or weakly bound proteins are removed from the column by washing several times with 0.5 ml of “TNI10 buffer”. Elution is carried out with 0.2 ml of “TNI150 buffer” (5 mM Tris-HCl pH 8.0; 300 mM NaCl; 150 mM imidazole). The elution fraction is analysed by western blot as in Example 1.

Results:

The eluates essentially contain proteins which, after staining of the western blot membrane with Ponceau S staining solution, in each case correspond to bands corresponding to a size of about 23-25 kDa. After western blot and detection of the His-tag, a bond corresponding to the same size can be seen. This result indicates that after the chromatography, the protein expressed is present in a form essentially free from E. coli constituents.

Example 3 Line Blots for Determination of Anti-OspC Antibodies with the Aid of the Recombinant OspC Variants

Nitrocellulose membranes are coated in lines with a purified recombinant OspC according to Example 2 diluted in 10% (w/v) glycerol (concentration: 20-100 μg/ml). The membranes are then dried overnight, blocked for 1 hour with “universal buffer” (EUROIMMUN), fixed on a solid phase, cut into strips about 2 mm wide with a scalpel at a 90° angle to the OspC lines, and then stored at 4° C. in aluminium bags with desiccant bags until used. The strips are incubated as described in the working instructions for EUROLINE-WB strips (EUROIMMUN), which are incubated as a comparison. Incubation of recomLine Borrelia strips (Microgen) in accordance with the manufacturer's instructions serves as a further comparison.

For determination of the sensitivity and specificity, 25 serum samples from patients with confirmed early phase of a Borrelia infection and 50 serum samples from pregnant women (which frequently contain non-specific antibodies) without signs of a Borrelia infection and 25 serum sample pairs from healthy persons taken at an interval of 14 days are analysed with respect to the presence of OspC-specific antibodies of immunoglobulin class M (IgM). Positive reactions in the healthy persons are checked by analysis of the IgG seroconversion (comparison of day 0/day 14) with several test systems for detection of antibodies of the IgG class against Borrelia, e.g. EUROLINE-WB IgG and anti-Borrelia ELISA IgG (EUROIMMUN). In no case of positive reaction, the follow-up sample gave indications of seroconversion.

TABLE 1 EURO- His-Cys-m- His-m- recomline LINE- OspC_(VS461) OspC_(VS461) Borrelia IgM WB SEQ ID SEQ ID Borrelia IgM NO: 2 NO: 1 afzelii n Anti-OspC IgM Early phase [n]  20 17 17 17 19 Sensitivity [%]  20 85 85 85 95 Healthy  50 2 2 6 8 pregnant women [n] Healthy blood  25 4 4 7 9 donors [n] Specificity [%]  75 92 92 82.7 77.3 Diagnostic 100 90.5 90.5 83.2 81.1 accuracy [%]

Results:

The results are summarized by way of example for OspC from B. afzelii in Table 1.

A large proportion of the sera of patients in an early phase of Borrelia infection contain IgM antibodies against OspC. In the study, the western blot with the native OspC originating from B. afzelii and the line blot with His-Cys-m-OspC_(VS461) have virtually equivalent sensitivities and specificities and at the same time the highest diagnostic accuracies. The line blot with the variant His-m-OspC_(VS461) and the recombinant OspC from B. afzelii on the recomBlot Borrelia IgM, in contrast, are distinguished above all by non-specific reactions in the healthy persons.

Example 4 Analysis of the Recombinant OspC Variants

In accordance with Example 2, the various purified OspC variants are separated by SDS-PAGE. In this context, the separation is carried out both under non-reducing conditions, under reducing conditions in the presence of dithiothreitol (DTT) and under alkylating conditions in the presence of iodoacetamide after DTT reduction. Thereafter, a western blot is carried out in accordance with Example 1. In parallel with the monoclonal antibodies against the His-tag described in Example 1, anti-OspC IgM positive sera are also incubated in a 1:200 dilution in accordance with Example 3. In the case of human sera, a conjugate of anti-human IgM and alkaline phosphatase (EUROIMMUN) diluted 1:10 in “universal buffer” is used in the second incubation step.

Results:

The separation under reducing and alkylating conditions, both after Ponceau S staining and after detection of the His-tag in accordance with Example 1, in each case leads to bands corresponding to a size of about 23-25 kDa. This also applies to the variants His-m-OspC_(VS461) (SEQ ID NO:1), His-m-OspC₂₀₀₄₇ (SEQ ID NO:4) and His-m-OspC_(B31) (SEQ ID NO:7) under non-reducing conditions. In contrast, in the case of the variants His-Cys-m-OspC_(VS461) (SEQ ID NO:2), His-Cys-m-OspC₂₀₀₄₇ (SEQ ID NO:5) and His-Cys-m-OspC_(B31) (SEQ ID NO:8), in each case two bands are present at 23-25 and 45-50 kDa, which are each stained approximately with the same intensity. These results indicate that the variants His-Cys-m-OspC_(VS461), His-Cys-m-OspC₂₀₀₄₇ and His-Cys-m-OspC_(B31) are each present as dimmers, in which in each case two monomers are linked to one another via disulphide bridges (see FIG. 2).

After incubation with human sera, the distribution of the bands in the particular variants is identical. It is striking, however, that the bands at 45-50 kDa are in each case stained considerably more intensively than the bands at 23-25 kDa. The different colour intensities after direct staining by Ponceau S and immunological staining after incubation with human sera indicate that the dimers in each case have higher specific reactivities than the monomers (see FIG. 2).

Example 5 Preparation of Heterodimers

Aliquots of two of the OspC dimer variants purified in accordance with Example 2, e.g. His-m-Cys-OspC_(VS461) and His-m-Cys-OspC₂₀₀₄₇ are mixed with one another in equal portions. An aliquot of the mixture is stored for analysis. The remainder is reduced by addition of DTT and the success of the reduction is checked by non-reducing SDS-PAGE and western blot in accordance with Example 4. The mixture is then freed from DTT by exhaustive dialysis against 20 mM Tris-HCl pH 8.5 and compressed air is passed through for 24 hours through a pipette tip in order to create an oxidative medium. The mixture is finally analysed by non-reducing isoelectric focussing between pH 6 and 9 with the ZoomRunner system (Invitrogen) in accordance with the manufacturer's instructions, subsequent reducing SDS-PAGE and western blot. The two individual OspC dimers and the mixture before addition of DTT are analysed for comparison.

Results:

His-m-Cys-OspC_(VS461) has a spot corresponding to approx. pH 7.5 and 24 kDa, His-m-OspC₂₀₀₄₇ on the other hand corresponding to approx. pH 6.5 and 24 kDa. The mixture of His-m-OspC_(VS461) and His-m-OspC₂₀₀₄₇ before reduction has two spots corresponding to approx. pH 7.5/24 kDa and pH 6.5/24 kDa. In contrast, the reduced and subsequently air-oxidized mixture has three spots corresponding to approx. pH 7.5/24 kDa, pH 6.8/24 kDa and pH 6.5/24 kDa. The results indicate that heterodimers are at least partly present.

Example 6 Immunogenicity of OspC Dimers with Disulphide Bridges

The proteins His-m-OspC_(VS461) and His-Cys-m-OspC_(VS461) purified in accordance with Example 2 were injected subcutaneously without an adjuvant into 10 female C3H/He mice, respectively, aged from four to six weeks for the first time and then at an interval of 14, 28 and 42 days in portions of in each case 100 μg per dose. Further 10 mice are injected with 0.9% (w/v) saline solution as a control, respectively. Blood is taken from all animals on the day of the first injection and then after 24, 38, 52 and 66 days. OspC-specific antibodies are determined in a 1:1,000 dilution of the particular serum with the aid of an anti-Borrelia IgM ELISA (EUROIMMUN), in which the conjugate for detection of bound human antibodies is exchanged for a conjugate, diluted 1:2,000 in conjugate dilution buffer (EUROIMMUN), for detection of bound murine antibodies of the IgG class (Dianova). The mean (MW) and standard deviation (a) of the results of in each case 10 animals treated in the same way are determined.

To check the specificity of the immune response, the 30 serum samples from the day of the last removal of blood are incubated on EUROLINE-WB strips (EUROIMMUN) in a 1:500 dilution and the bound murine antibodies are detected in accordance with experiment 1.

Results:

The results are given as extinction at 450 nm and are summarized in Table 2.

TABLE 2 Day 0 24 38 52 66 Antigen n MW σ MW σ MW σ MW σ MW σ 0.9% (w/v) NaCl 10 0.015 0.002 0.019 0.004 0.019 0.006 0.014 0.002 0.024 0.005 solution His-m-OspC_(VS461) 10 0.014 0.003 0.017 0.003 0.069 0.114 0.722 0.986 2.195 1.518 His-m-Cys-OspC_(VS461) 10 0.014 0.002 0.036 0.024 1.043 0.995 1.892 1.288 3.868 0.202

It is found that considerably faster and higher measurement values are generated if the animals have been immunized with the variant His-m-Cys-OspC_(VS461). It is furthermore found that at the end of the immunization programme, all the sera of animals immunized with the variant His-m-Cys-OspC_(VS461) generate high measurement values close to the mean. In contrast, very low or low measurement values in some of the animals which were immunized with the variant His-m-OspC_(VS461) indicate that the immunization in these animals did not lead to a substantial antibody titre.

The incubation on EUROLINE-WB strips shows that all the sera which generate an increased extinction (E_(450 nm)≧0.3) in ELISA generate a band at the migration site of the OspC. In this context, the band intensity approximately correlates with the extinction.

The two results taken together suggest that the mice which were immunized with the variant His-m-Cys-OspC_(VS461) generate antibodies faster than after immunization with the variant His-m-OspC_(VS461), and that higher antibody concentrations are achieved at the end of the immunization.

The various embodiments described above can be combined to provide further embodiments. All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet are incorporated herein by reference, in their entirety. Aspects of the embodiments can be modified, if necessary to employ concepts of the various patents, applications and publications to provide yet further embodiments.

These and other changes can be made to the embodiments in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.

LITERATURE LIST

-   1 Cutler S J, Wright D J: Comparison of immunofluorescence and     enzyme linked immunosorbent assays for diagnosing Lyme disease. J     Clin Pathol 42:869-871 (1989). -   2 Earnhart C G, Buckles E L, Dumler J S, Marconi R T: Demonstration     of OspC type diversity in invasive human lyme disease isolates and     identification of previously uncharacterized epitopes that define     the specificity of the OspC murine antibody response. Infect Immun     73:7869-7877 (2005). -   3 Eicken C, Sharma V, Klabunde T, Owens R T, Pikas D S, Hook M,     Sacchettini J C: Crystal structure of Lyme disease antigen outer     surface protein C from Borrelia burgdorferi. J Biol Chem     276:10010-10015 (2001). -   4 Fister R D, Weymouth L A, McLaughlin J C, Ryan R W, Tilton R C:     Comparative evaluation of three products for the detection of     Borrelia burgdorferi antibody in human serum. J Clin Microbiol     27:2834-2837 (1989). -   5 Fuchs R, Jauris S, Lottspeich F, Preac-Mursic V, Wilske B,     Soutschek E: Molecular analysis and expression of a Borrelia     burgdorferi gene encoding a 22 kDa protein (pC) in Escherichia coli.     Mol Microbiol 6:503-509 (1992). -   6 Hagman K E, Landenne P, Popova T G, Porcella S F, Akins D R,     Radolf J D, Norgard M V: Decorin-binding protein of Borrelia     burgdorferi is encoded within a two-gene operon and is protective in     the murine model of Lyme borreliosis. Infect Immun 66:2674-2683     (1998). -   7 Hansen K, Hindersson P, Pedersen N S: Measurement of antibodies to     the Borrelia burgdorferi flagellum improves serodiagnosis in Lyme     disease. J Clin Microbiol 26:338-346 (1988). -   8 Hauser U, Lehnert G, Wilske B: Diagnostic value of proteins of     three Borrelia species (Borrelia burgdorferi sensu lato) and     implications for development and use of recombinant antigens for     serodiagnosis of Lyme borreliosis in Europe. Clin Diagn Lab Immunol     5:456-462 (1998). -   9 Hyde J A, Trzeciakowski J P, Skare J T: Borrelia burgdorferi     alters its gene expression and antigenic profile in response to CO2     levels. J Bacteriol 189:437-445 (2007). -   10 Kumaran D, Eswaramoorthy S, Luft B J, Koide S, Dunn J J, Lawson C     L, Swaminathan S: Crystal structure of outer surface protein C     (OspC) from the Lyme disease spirochete, Borrelia burgdorferi. EMBO     J 20:971-978 (2001). -   11 Lawrenz M B, Hardham J M, Owens R T, Nowakowski J, Steere A C,     Wormser G P, Norris S J: Human antibody responses to VIsE antigenic     variation protein of Borrelia burgdorferi. J Clin Microbiol     37:3997-4004 (1999). -   12 Mathiesen M J, Christiansen M, Hansen K, Holm A, Asbrink E,     Theisen M: Peptide-based OspC enzyme-linked immunosorbent assay for     serodiagnosis of Lyme borreliosis. J Clin Microbiol 36:3474-3479     (1998a). -   13 Mathiesen M J, Holm A, Christiansen M, Blom J, Hansen K,     Ostergaard S, Theisen M: The dominant epitope of Borrelia garinii     outer surface protein C recognized by sera from patients with     neuroborreliosis has a surface-exposed conserved structural motif.     Infect Immun 66:4073-4079 (1998b). -   14 Norris S J, Carter C J, Howell J K, Barbour A G:     Low-passage-associated proteins of Borrelia burgdorferi B31:     characterization and molecular cloning of OspD, a surface-exposed,     plasmid-encoded lipoprotein. Infect Immun 60:4662-4672 (1992). -   15 Pollack R J, Telford S R, III, Spielman A: Standardization of     medium for culturing Lyme disease spirochetes. J Clin Microbiol     31:1251-1255 (1993). -   16 Ruzic-Sabljic E, Strle F: Comparison of growth of Borrelia     afzelii, B. garinii, and B. burgdorferi sensu stricto in MKP and     BSK-II medium. Int J Med Microbiol 294:407-412 (2004). -   17 Seshu J, Boylan J A, Gherardini F C, Skare J T: Dissolved oxygen     levels alter gene expression and antigen profiles in Borrelia     burgdorferi. Infect Immun 72:1580-1586 (2004). -   18 Wilske B, Fingerle V: Lyme-Borreliose Diagnostik (2005). -   19 Wilske B, Jauris-Heipke S, Lobentanzer R, Pradel I, Preac-Mursic     V, Rossler D, Soutschek E, Johnson R C: Phenotypic analysis of outer     surface protein C (OspC) of Borrelia burgdorferi sensu lato by     monoclonal antibodies: relationship to genospecies and OspA     serotype. J Clin Microbiol 33:103-109 (1995). -   20 Wilske B, Preac-Mursic V, Jauris S, Hofmann A, Pradel I,     Soutschek E, Schwab E, Will G, Wanner G: Immunological and molecular     polymorphisms of OspC, an immunodominant major outer surface protein     of Borrelia burgdorferi. Infect Immun 61:2182-2191 (1993). -   21 Wu H C, Tokunaga M: Biogenesis of lipoproteins in bacteria. Curr     Top Microbiol Immunol 125:127-157 (1986). -   22 Yang X, Popova T G, Goldberg M S, Norgard M V: Influence of     cultivation media on genetic regulatory patterns in Borrelia     burgdorferi. Infect Immun 69:4159-4163 (2001). -   23 WO 9742221 -   24 EP1741718 

The invention claimed is:
 1. A vaccine against a Borrelia infection comprising a protein, said protein comprising a first OspC polypeptide comprising one or more cysteines and a second OspC polypeptide comprising one or more cysteines, wherein the first OspC polypeptide is linked to the second OspC polypeptide via a disulphide bridge formed between the most N-terminal cysteines in the first and second OspC polypeptides, and wherein both the first and second OspC polypeptides comprise at least one epitope that is specifically recognized by antibodies against OspC from Borrelia, the epitope comprising at least 10 contiguous amino acids from SEQ ID NO:3, SEQ ID NO:6, or SEQ ID NO:9.
 2. The vaccine according to claim 1, wherein both the first and second OspC polypeptides have an amino acid identity of at least 90% with SEQ ID NO:3, SEQ ID NO:6 or SEQ ID NO:9.
 3. The vaccine according to claim 1, wherein the at least 10 contiguous amino acids from SEQ ID NO:3, SEQ ID NO:6 or SEQ ID NO:9 are the 10 C-terminal amino acids of these sequences and said at least 10 contiguous amino acids are in the C-terminal location of the OspC polypeptide.
 4. The vaccine according to claim 1, wherein the first OspC polypeptide, the second OspC polypeptide, or both the first and second OspC polypeptides do not comprise any recognition sequence for an acylation.
 5. The vaccine according to claim 1, wherein the disulphide bridge is formed by linking of a cysteine which is not more than 30 amino acid positions away from the N-terminus of the first OspC polypeptide, the second OspC polypeptide, or both the first and second OspC polypeptides.
 6. The vaccine according to claim 1, wherein the first OspC polypeptide, the second OspC polypeptide, or both the first and second polypeptides comprise a sequence according to SEQ ID NO:2, SEQ ID NO:5 or SEQ ID NO:8.
 7. The vaccine according to claim 1, wherein by means of the disulphide bridge a homodimer of two identical OspC polypeptides is formed.
 8. The vaccine according to claim 1, wherein the recognition of the polypeptide by antibodies against OspC from Borrelia would be reduced by bringing the protein into contact with at least one thiol-containing reagent.
 9. The vaccine according to claim 1, wherein by means of the disulphide bridge a heterodimer of different OspC polypeptides is formed.
 10. The vaccine according to claim 1, wherein the recognition of the polypeptide by antibodies against OspC from Borrelia would be reduced by bringing the protein into contact with at least one thiol-containing reagent in combination with an alkyl halide. 